Treace Medical Concepts

TMCI · NASDAQ

$4.07+$0.19 (+4.90%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.88

TMCI analyst rating

HoldConsensus of 6 analysts over the last 12 months. 17% rate it a buy.

Strong buy0
Buy1
Hold4
Underperform1
Sell0

12-month price target · 5 analysts

Average $5.61 (+37.8% upside)

Low: $4.55
Now: $4.07
High: $7.35

Upgrades and downgrades

The latest rating actions, newest first

TMCI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Aug 10, 2026	Maintains	Hold	$4.00 → $5.00	50%
Truist Securities	Jul 16, 2026	Maintains	Hold	$2.00 → $4.00	50%
Lake Street	Mar 2, 2026	Maintains	Buy	$7.50 → $7.00	41%
Stifel	Jan 7, 2026	Maintains	Hold	$5.00 → $3.00	62%
Truist Securities	Dec 18, 2025	Maintains	Hold	$4.00 → $3.00	50%
Truist Securities	Nov 10, 2025	Maintains	Hold	$7.00 → $4.00	50%
UBS	Nov 7, 2025	Maintains	Neutral	$6.50 → $5.85	50%
JP Morgan	Nov 7, 2025	Downgrade	Neutral → Underweight	$8.00 → $5.00	50%
BTIG	Nov 7, 2025	Downgrade	Buy → Neutral	—	48%

The case for and against

Updated Apr 28, 2026

Bull case

Treace Medical Concepts is facing short-term challenges due to lower bunion surgery volumes, a shift towards less complex MIS products, and increased competition in the market. While the company has a strong product portfolio, it will take time for them to stabilize and regain market share. TMCI's valuation and growth prospects may be impacted in the near term, but the long-term potential remains strong in the bunion surgery market.

Bear case

Treace Medical Concepts is a company that has had multiple guidance resets over the past 2 years and is currently facing significant headwinds in their core business, with the possibility of negative growth in 2026. This has led to a decrease in price targets and a continued multiple discount compared to peers. Even with new product launches and pipeline innovations, there is uncertainty about when the company will be able to return to positive growth in an increasingly competitive market. In addition, increased competition, declining demand for elective foot surgery, and pressure on average selling prices are all factors that could hinder the company's ability to improve its financials and stock performance in the near term.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.